Press releases

1,536 human brain organoids modeling Alzheimer’s, Parkinson’s and frontotemporal dementia fly on SPX-35 to the International Space Station, as the company’s first Nanoligomer™ medicine prepares to enter human trials in ALS ERIE, Colo., Oct. 13, 2026 — Sachi Bio (Sachi Bioworks, Inc.), a clinical-stage biopharmaceutical company developing Nanoligomer™ medicines for neurodegenerative and inflammatory diseases, today sent 1,536 human brain organoids to the International Space St

Multi-Organ Tissue Models Head to the International Space Station to Accelerate Discovery for Neurological, Cardiac, Metabolic, and Systemic Diseases ERIE, CO – July 1, 2026 — Sachi Bio, a biotechnology company pioneering RNA-based therapeutics through its proprietary Nanoligomer™ platform, announced the successful completion of an orbital mission that advanced ADDISTM (Accelerated Drug Discovery in Space)—the company’s multi-organ, multi-indication discovery platform. The

Sachi Bio proudly participated in the recent ALS Walk held in Denver, Colorado, organized by the ALS United Rocky Mountain, standing in...

Sachi Bio's lead program NI112 shows excellent Safety-Toxicity, brain-delivery, and biodistribution profile in Investigational New Drug...

"Sachi Bio has successfully advanced it's lead program towards translation for a range of neurodegenerative diseases, as well as a...